Pharmacology/Pharmaceutical Industry | Page 16 of 172 | Links Medicus Content Curation & Alerts in Medicine

Phase 2 RCT | Small interfering RNA to reduce Lipoprotein(a) in cardiovascular disease.

8 Nov, 2022 | 12:30h | UTC

Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Clinical trial finds novel therapy markedly reduced lipoprotein(a) levels in people with cardiovascular disease – Brigham and Women’s Hospital

Commentary on Twitter

Lipoprotein(a) is similar to LDL cholesterol but contains apolipoprotein(a). A trial tested the effects of an oligonucleotide drug targeting apo(a) mRNA on lipoprotein(a) concentrations in patients with CVD. #AHA22 https://t.co/eLgnrnTm5D pic.twitter.com/QmNUcxeJwX

— NEJM (@NEJM) November 6, 2022

Review | Oral anticoagulant use in patients with atrial fibrillation and chronic kidney disease.

8 Nov, 2022 | 12:02h | UTC

Oral Anticoagulant Use in Patients With Atrial Fibrillation and Chronic Kidney Disease: A Review of the Evidence With Recommendations for Australian Clinical Practice – Heart Lung and Circulation

CDC Clinical Practice Guideline for prescribing opioids for pain.

7 Nov, 2022 | 13:00h | UTC

CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022 – Morbidity and Mortality Weekly Report

Commentaries:

Prescribing Opioids for Pain — The New CDC Clinical Practice Guideline – New England Journal of Medicine

CDC issues new opioid prescribing guidance, giving doctors more leeway to treat pain – NPR

RCT | In patients with CKD (eGFR 20-45 mL/min per 1.73 m2), Empagliflozin reduced the risk of progression of kidney disease.

7 Nov, 2022 | 12:56h | UTC

Empagliflozin in Patients with Chronic Kidney Disease – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: EMPA-KIDNEY supports SGLT2 inhibition for chronic kidney disease – medwire News

Video Summary: EMPA-KIDNEY results: Empagliflozin reduces kidney disease progression and cardiovascular deaths

Commentary on Twitter

In this trial involving patients with chronic kidney disease, empagliflozin resulted in a lower risk of disease progression or death from cardiovascular causes than placebo. #KidneyWk https://t.co/HFgzPgrRFx pic.twitter.com/EPU6Rl14F1

— NEJM (@NEJM) November 4, 2022

Phase 2 RCT | Single-dose Psilocybin for a treatment-resistant episode of major depression.

4 Nov, 2022 | 13:57h | UTC

Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression – New England Journal of Medicine (link to abstract – $ for full-text)

Commentaries:

Largest trial to date shows that psilocybin reduces depression symptoms – King’s College London

Expert reaction to Phase IIb Clinical Trial of Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression – Science Media Centre

RCT | In patients with alcohol use disorder, the percentage of heavy drinking days was reduced with a psychedelic drug.

Phase 2 RCT: Psilocybin, a psychedelic compound, shows promise for the treatment of depression in a study with 59 patients

Research: “Magic mushrooms” for treatment-resistant depression

Commentary on Twitter

A single 25-mg dose of psilocybin was more effective than a 1-mg dose at alleviating treatment-resistant depression over a period of 3 weeks. The effect was attenuated at 12 weeks. https://t.co/sM1mISArvb pic.twitter.com/9YRaxfcpNT

— NEJM (@NEJM) November 2, 2022

RCT | Once-weekly Semaglutide effective for weight loss in adolescents with obesity.

4 Nov, 2022 | 13:59h | UTC

Once-Weekly Semaglutide in Adolescents with Obesity – New England Journal of Medicine (link to abstract – $ for full-text)

Commentaries:

STEP TEENS: High-dose semaglutide weight loss benefits shown in adolescents – medwire News

Trial Shows Weight-Loss Drug Works in Teens – HealthDay

Commentary on Twitter

In this trial, adolescents with obesity assigned to weekly subcutaneous semaglutide plus lifestyle intervention had a greater reduction in BMI than those who received lifestyle intervention alone. https://t.co/yiFseP38xa pic.twitter.com/uRqkFfon1s

— NEJM (@NEJM) November 2, 2022

Guideline on prescribing drugs in pregnancy and breastfeeding: comorbidity medications used in rheumatology practice.

4 Nov, 2022 | 13:42h | UTC

British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: comorbidity medications used in rheumatology practice – Rheumatology

Executive Summary: British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: comorbidity medications used in rheumatology practice – Rheumatology

Guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids.

4 Nov, 2022 | 13:44h | UTC

British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids – Rheumatology

Executive Summary: British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids – Rheumatology

M-A | Risk of major adverse events associated with gabapentinoid and opioid combination therapy.

4 Nov, 2022 | 13:13h | UTC

Risk of major adverse events associated with gabapentinoid and opioid combination therapy: A systematic review and meta-analysis – Frontiers in Pharmacology

USPSTF Statement | Hormone therapy is not recommended for the prevention of chronic conditions in postmenopausal women.

3 Nov, 2022 | 14:19h | UTC

Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons: US Preventive Services Task Force Recommendation Statement – JAMA

Editorial: Menopausal Hormone Therapy for Prevention of Chronic Conditions: When Is Enough, Enough? – JAMA

Evidence Report: Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force – JAMA

JAMA Patient Page: Menopausal Hormone Therapy for Prevention of Chronic Conditions

Author Interview: USPSTF Recommendation: Hormone Therapy for Prevention of Postmenopausal Chronic Conditions – JAMA

Commentary: USPSTF: Hormone Therapy Not Advised for Primary Prevention of Chronic Conditions – HealthDay

ACCP Guideline | Perioperative management of antithrombotic therapy.

1 Nov, 2022 | 12:18h | UTC

Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline – CHEST

Executive Summary: Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline – CHEST

Commentary on Twitter

2022 guideline for perioperative management of VKAs, heparin bridging, DOACs & antiplatelets
Pts requiring elective surgery, in general,🛑💊 before surgery
👉VKAs 3-5d
👉DOACS 1-2d
👉P2Y12 receptor inhibitors 3-7d✅drug specificshttps://t.co/RYNrEOovRe @SCCM_Surgery @SCCM_CPP

— Lauren R. Sorce, PhD, RN, CPNP-AC/PC, FAAN, FCCM (@SCCMPresident) August 26, 2022

M-A | Association of SGLT2 inhibitors with cardiovascular outcomes and safety events.

1 Nov, 2022 | 11:56h | UTC

Association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcome and safety events: A meta-analysis of randomized controlled clinical trials – Frontiers in Cardiovascular Medicine

Dose-reduced direct oral anticoagulants: practical considerations.

31 Oct, 2022 | 13:52h | UTC

Peripheral Matters | Dose-Reduced Direct Oral Anticoagulants: Practical Considerations – American College of Cardiology

Optimizing medication use in older adults with rheumatic diseases: deprescribing as an approach when less may be more.

26 Oct, 2022 | 14:33h | UTC

Optimizing Medication Use in Older Adults With Rheumatic Musculoskeletal Diseases: Deprescribing as an Approach When Less May Be More – ACP Open Rheumatology

Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy – European Heart Journal – Cardiovascular Pharmacotherapy

Deprescribing in Older Adults with Cardiovascular Disease – Journal of the American College of Cardiology

Multimorbidity in Older Adults with Cardiovascular Disease – American College of Cardiology, Latest in Cardiology

Deprescribing medicines in older people living with multimorbidity and polypharmacy: the TAILOR evidence synthesis – Health Technology Assessment

Antihypertensive Deprescribing in Older Adults: a Practical Guide – Current Hypertension Reports

How-to guide for medication reviews in older adults with cancer: A Young International Society of Geriatric Oncology and Nursing & Allied Health Interest Group initiative – Journal of Geriatric Oncology

Deprescribing in Palliative Cancer Care – Life

Less is More: Deprescribing Medications in Older Adults with Kidney Disease: A Review – Kidney360

Process evaluation of implementation strategies to reduce potentially inappropriate medication prescribing in older population: A scoping review – Research in Social and Administrative Pharmacy

AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review – Gastroenterology

Development of a Metric to Detect and Decrease Low-Value Prescribing in Older Adults – JAMA Network Open

The MedSafer Study—Electronic Decision Support for Deprescribing in Hospitalized Older Adults: A Cluster Randomized Clinical Trial – JAMA Internal Medicine

Quantifying Anticholinergic Burden and Sedative Load in Older Adults with Polypharmacy: A Systematic Review of Risk Scales and Models – Drugs & Aging

Deprescribing in palliative patients with cancer: a concise review of tools and guidelines – Supportive Care in Cancer

Prescribing practices, patterns, and potential harms in patients receiving palliative care: A systematic scoping review – Exploratory Research in Clinical and Social Pharmacy

A narrative review of evidence to guide deprescribing among older adults – Journal of General and Family Medicine

Polypharmacy, inappropriate prescribing, and deprescribing in older people: through a sex and gender lens – The Lancet Health Longevity

Polypharmacy Management in Older Patients – Mayo Clinic Proceedings

Psychopharmacological Treatment in Older People: Avoiding Drug Interactions and Polypharmacy – Deutsches Ärzteblatt international

Eliminating Medication Overload: A National Action Plan – Lown Institute

International Group for Reducing Inappropriate Medication Use & Polypharmacy (IGRIMUP): Position Statement and 10 Recommendations for Action – Drugs & Aging

Common ED Medication Errors: Polypharmacy – emDocs

Current and future perspectives on the management of polypharmacy – BMC Family Practice

Routine deprescribing of chronic medications to combat polypharmacy – Therapeutic Advances in Drug Safety

Polypharmacy—an Upward Trend with Unpredictable Effects – Deutsches Ärzteblatt international

Clinical Consequences of Polypharmacy in Elderly – Expert Opinion on Drug Safety

M-A | Age, sex, race, BMI, and duration of type 2 DM differences in cardiovascular outcomes with glucose lowering drugs.

26 Oct, 2022 | 14:32h | UTC

Age, sex, race, BMI, and duration of diabetes differences in cardiovascular outcomes with glucose lowering drugs in type 2 diabetes: A systematic review and meta-analysis – eClinicalMedicine

Commentary: Meta-analysis may guide optimal type 2 diabetes glucose-lowering agent for MACE protection – medwire News

KDIGO 2022 Clinical practice guideline for diabetes management in chronic kidney disease.

24 Oct, 2022 | 14:16h | UTC

KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease – Kidney International

Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

24 Oct, 2022 | 14:12h | UTC

Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up – Annals of Oncology

AGA clinical practice guideline on pharmacological interventions for adults with obesity.

21 Oct, 2022 | 13:06h | UTC

AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity – Gastroenterology

News Release: First medical guideline recommends new prescription medications for weight loss, ranks the most effective drugs – American Gastroenterological Association

Pooled analysis of cohort studies | Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters.

19 Oct, 2022 | 14:28h | UTC

Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales – The Lancet

Commentaries:

Prioritisation of COVID-19 boosters in the omicron era – The Lancet

COVID booster halved severe illness, but some groups still at higher risk – CIDRAP

Case-control study | Odds of hospitalization for COVID-19 after 3 vs. 2 doses of mRNA vaccine by time since booster dose.

19 Oct, 2022 | 14:27h | UTC

Odds of Hospitalization for COVID-19 After 3 vs 2 Doses of mRNA COVID-19 Vaccine by Time Since Booster Dose – JAMA

News Release: Study indicates COVID-19 boosters among vaccinated individuals significantly reduce hospitalization rates – Providence Health & Services

M-A | Proactive therapeutic drug monitoring vs. conventional management for inflammatory bowel diseases.

18 Oct, 2022 | 12:42h | UTC

Proactive Therapeutic Drug Monitoring Versus Conventional Management for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis – Gastroenterology

Commentary on Twitter

October's Editor's Essential Reading examines proactive therapeutic drug monitoring versus conventional management for inflammatory bowel diseases @vipuljairath @ChrisMa_YYC https://t.co/kNAia4yowO pic.twitter.com/wfgQSQtM1O

— Gastroenterology (@AGA_Gastro) September 28, 2022

Fungal infections | Pathogenesis, antifungals and alternate treatment approaches.

17 Oct, 2022 | 12:24h | UTC

Fungal infections: Pathogenesis, antifungals and alternate treatment approaches – Current Research in Microbial Sciences

Commentary on Twitter

Fungal infections:

Pathogenesis, antifungals and alternate treatment approacheshttps://t.co/JMcmzsL3GA #OpenAccess pic.twitter.com/5xAi5IGRGf

— MicrobesInfect (@MicrobesInfect) April 27, 2022

Under a Creative Commons license

Participation of older adults in clinical trials for new drug applications and biologics license applications from 2010-2019.

17 Oct, 2022 | 12:12h | UTC

Participation of Older Adults in Clinical Trials for New Drug Applications and Biologics License Applications From 2010 Through 2019 – JAMA Network Open

Commentary on Twitter

Underrepresentation of adults above age 75-80 years found in evaluation of new medications. 60-75 year-olds were reasonably well represented in clinical trials in proportion to the prevalence data in the US. #OAResearch https://t.co/2RL5fTo3LA

— JAMA Network Open (@JAMANetworkOpen) October 14, 2022

Incidence of myocarditis/pericarditis following mRNA COVID-19 vaccination among children and younger adults in the US.

13 Oct, 2022 | 13:51h | UTC

Incidence of Myocarditis/Pericarditis Following mRNA COVID-19 Vaccination Among Children and Younger Adults in the United States – Annals of Internal Medicine

News Release: Incidence of myocarditis/pericarditis following mRNA COVID-19 vaccination among children, younger adults in the US – American College of Physicians

Commentary on Twitter (thread – click for more)

Let me me perfectly clear about the evidence for myocarditis after mRNA vaccines
1. There is a notable increased incidence, age 12-39, males, with each dose (Table)https://t.co/XXQbyeLiSP pic.twitter.com/wLTZT3fppy

— Eric Topol (@EricTopol) October 12, 2022

Commentary on Twitter

Let me me perfectly clear about the evidence for myocarditis after mRNA vaccines
1. There is a notable increased incidence, age 12-39, males, with each dose (Table)https://t.co/XXQbyeLiSP pic.twitter.com/wLTZT3fppy

— Eric Topol (@EricTopol) October 12, 2022

Benefits and risks associated with continuation of anti–TNF after 24 weeks of pregnancy in inflammatory bowel disease.

12 Oct, 2022 | 13:52h | UTC

Benefits and Risks Associated With Continuation of Anti–Tumor Necrosis Factor After 24 Weeks of Pregnancy in Women With Inflammatory Bowel Disease – Annals of Internal Medicine (link to abstract – $ for full-text)

News Release: Anti-TNF continuation after 24 weeks of pregnancy beneficial to persons with IBD, does not affect neonatal outcomes – American College of Physicians

Commentary: Continuation of Anti-TNF for IBD After 24 Weeks of Pregnancy Beneficial – HealthDay

Commentary on Twitter

10 year trial found continuation of #AntiTNF treatment after 24 weeks of pregnancy appears beneficial for #IBD activity and prematurity, not affecting neonatal outcomes and serious infections in the offspring. @EPIPHARE https://t.co/YuytSQqDsE pic.twitter.com/CRGN80K93A

— Annals of Int Med (@AnnalsofIM) September 27, 2022

Stay Updated in Your Specialty